Citations

Mayo Clinic

Showing 10 of 108585 citations.

Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients
Rajkumar, S. Vincent , Abdallah, Nadine , Kumar, Shaji , Cook, Joselle , Binder, Moritz , Kapoor, Prashant , Gertz, Morie A. , Lacy, Martha Q. , Hayman, Suzanne R. , Kourelis, Taxiarchis , Warsame, Rahma , Bergsagel, P. Leif , Bergsagel, P. Leif , Rajkumar, S Vincent , Kumar, Shaji K , Cook, Joselle M , Binder, Moritz , Kapoor, Prashant , Dispenzieri, Angela , Gertz, Morie A , Lacy, Martha, Buadi, Francis K , Dingli, David , Lin, Yi , Kourelis, Taxiarchis , Lakshman, Arjun , Dispenzieri, Angela , Buadi, Francis K. , Dingli, David , Lin, Yi

No container title available | October 23, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3378634/v1 | PMID 37961238 Get It

Abstract The approach to patients with high-risk smoldering multiple myeloma (SMM) varies among clinicians; while some advocate early intervention, others reserve treatment at progression to multiple myeloma (MM). We aimed to describe the myeloma-defining events (MDEs) and clinical presentations leading to MM diagnosis among SMM patients seen at our institution. We included 406 patients diagnosed with SMM between 2013-2022, seen at Mayo Clinic, Rochester, MN. The 2018 Mayo 20/2/20 criteria were used for risk stratification. Median follow-up was 3.9 years. Among high-risk patients who did not receive treatment in the SMM phase (n=71), 51 progressed by last follow-up; the MDEs included: bone lesions(37%), anemia(35%), hypercalcemia(8%), and renal failure(6%); 24% met MM criteria based on marrow plasmacytosis (≥60%) and/or free light chain ratio (>100); 45% had clinically significant MDEs (hypercalcemia, renal insufficiency, and/or bone lesions). MM diagnosis was made based on surveillance labs/imaging(45%), testing obtained due to provider suspicion for progression(14%), bone pain(20%), and hospitalization/ED presentations due to MM complications/symptoms(4%). The presentation was undocumented in 14%. A high proportion (45%) of patients with high-risk SMM on active surveillance develop end-organ damage at progression. About a quarter of patients who progress to MM are not diagnosed based on routine interval surveillance testing.
Interventions to improve symptomatology in patients with hypothyroidism and persistent symptoms: A systematic review.
Hidalgo, Jessica, Codova-Madera, Sandra, Wenczenovicz, Camila , Rao, Arbaaz, Ospina, Naykky Singh , Acosta, Gonzalo J. , Brito, Juan P. , Brito, Juan P , Lincango-Naranjo, Eddy , Ruiz-Arellanos, Kim , Ponce, Oscar J. , Álvarez‐Villalobos, Neri Alejandro , Maraka, Spyridoula

No container title available | October 23, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3455335/v1 Get It

Abstract Background Levothyroxine (LT4) monotherapy is the standard treatment for hypothyroidism; however, 10–15% of patients have persistent hypothyroid symptoms despite normalizing thyroid hormone levels with LT4. This study aims to summarize the best available evidence on interventions to improve symptomatology in patients with hypothyroidism and persistent symptoms. Methods A systematic search was conducted in March 2022 for randomized controlled trials (RCTs) and observational studies on interventions for adult patients with persistent hypothyroid symptoms despite biochemical euthyroidism on thyroid hormone replacement. Results Of 277 articles, seven fulfilled the inclusion criteria. 455 participants were included. Most intervention participants were female (78.6%) with a mean age of 47.5 years. Five clinical trials evaluating ginger (vs. starch), L-carnitine (vs. placebo), combination LT4 and liothyronine (LT3) (vs. LT4 or placebo), and surgery for patients with serum antithyroid peroxidase (TPO Ab) titers greater than 1000 IU/ml (vs. LT4) found inconsistent improvement in hypothyroidism related symptoms and general health. Of these clinical trials, the use of ginger and surgery showed the largest improvements in fatigue scores. One observational study comparing thyroidectomy vs observation found no impact difference on general health. Lastly, another observational study evaluating combination LT4/LT3 (vs. LT4 monotherapy) found improvement in fatigue and QoL. There were 31 (12%) adverse events in the intervention group and 18 (10.8%) in the comparator group. Conclusions There is no high-quality evidence supporting any intervention for persistent symptoms in hypothyroidism. Available evidence, limited by the risk of bias, inconsistency, and heterogeneity, suggests that some persistent symptoms, particularly fatigue, could improve with ginger and thyroidectomy. Trial registry number:PROSPERO (CRD42022318720)
Neuropathologic evaluation of cerebrovascular disease in patients with rheumatoid arthritis
Larsen, Rachel A. , Constantopoulos, Eleni , Kodishala, Chanakya , Lovering, Edward , Hulshizer, Cassondra A., Lennon, Ryan J. , Crowson, Cynthia S. , Nguyen, Aivi T. , Myasoedova, Elena , Crowson, CS , Myasoedova, Elena , Nguyen, Aivi T , Kumar, Rakesh

Rheumatology | October 23, 2023 | Volume: 62 | Issue: SI3 | Pages: SI296-SI303

10.1093/rheumatology/kead396 | PMID 37871918 Get It

Abstract Objectives Active RA has been associated with an increased risk of both cardiovascular and peripheral vascular disease. We aimed to compare cerebrovascular changes in patients with and without RA, both with and without a neuropathologic diagnosis of neurodegenerative disease. Methods Patients with RA (n = 32) who died and underwent autopsy between 1994 and 2021 were matched to non-RA controls (n = 32) on age, sex and level of neurodegenerative proteinopathy. Routine neuropathologic examination was performed at the time of autopsy. Cerebrovascular disease severity was evaluated using modified Kalaria and Strozyk scales. Clinical dementia diagnoses were manually collected from patients’ medical records. Results Prior to death, 15 (47%) RA patients and 14 (44%) controls were diagnosed with dementia; 9 patients in each group (60% and 64%, respectively) had Alzheimer’s disease. The prevalence of cerebral amyloid angiopathy, microinfarcts, infarcts or strokes was found to be similar between groups. Patients with RA were more likely to have more severe vascular changes in the basal ganglia by Kalaria scale (P = 0.04), but not in other brain areas. There were no significant differences in the presence of large infarcts, lacunar infarcts or leukoencephalopathy by Strozyk scale. Among patients with RA and no clinical diagnosis of dementia, the majority had mild–moderate cerebrovascular abnormalities, and a subset of patients had Alzheimer’s disease neuropathologic changes. Conclusion In this small series of autopsies, patients with and without RA had largely similar cerebrovascular pathology when controlling for neurodegenerative proteinopathies, although patients with RA exhibited more pronounced cerebrovascular disease in the basal ganglia.
Left ventricle outflow tract obstruction after transcatheter mitral valve replacement with a transatrial approach
Farina, Juan M. , Jokerst, Clinton, Wilansky, Susan , Arsanjani, Reza , Arsanjani, Reza , Farina, Juan M , Sell‐Dottin, Kristen

European Heart Journal - Cardiovascular Imaging | October 23, 2023 | Volume: 25 | Issue: 3 | Pages: e108-e108

10.1093/ehjci/jead279 | PMID 37875138 Get It

Prominent tauopathy and intracellular β-amyloid accumulation triggered by genetic deletion of cathepsin D: Implications for Alzheimer disease pathogenesis
Terron, Heather M., Parikh, Sagar J., Abdul‐Hay, Samer O., Sahara, Tomoko, Kang, Dongcheul, Säftig, Paul , LaFerla, Frank M. , Lane, Shelley , Dickson, Dennis W. , Lane, Shelley, Leissring, Malcolm A.

No container title available | October 23, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3464352/v1 | PMID 37961253 Get It

Abstract Background Cathepsin D (CatD) is a lysosomal protease that degrades both the amyloid-β protein (Aβ) and the microtubule-associated protein, tau, which accumulate pathognomonically in Alzheimer disease (AD), but few studies have examined the role of CatD in the development of Aβ pathology and tauopathy in vivo. Methods CatD knockout (KO) mice were crossed to human amyloid precursor protein (hAPP) transgenic mice, and amyloid burden was quantified by ELISA and immunohistochemistry (IHC). Tauopathy in CatD-KO mice, as initially suggested by Gallyas silver staining, was further characterized by extensive IHC and biochemical analyses. Controls included human tau transgenic mice (JNPL3) and another mouse model characterized by pronounced lysosomal dysfunction (Krabbe A). Additional experiments examined the effects of CatD inhibition on tau catabolism in vitro and in cultured neuroblastoma cells with inducible expression of human tau. Results Deletion of CatD in hAPP transgenic mice triggers large increases in cerebral Aβ, manifesting as intense, exclusively intracellular aggregates; extracellular Aβ deposition, by contrast, is neither triggered by CatD deletion, nor affected in older, haploinsufficient mice. Unexpectedly, CatDKO mice were found to develop prominent tauopathy by just ~ 3 weeks of age, accumulating sarkosyl-insoluble, hyperphosphorylated tau exceeding the pathology in aged JNPL3 mice. CatDKO mice exhibit pronounced perinuclear Gallyas silver staining reminiscent of mature neurofibrillary tangles in human AD, together with widespread phospho-tau immunoreactivity. Striking increases in sarkosyl-insoluble phospho-tau (~ 1250%) are present in CatD-KO mice, but notably absent from Krabbe A mice collected at an identical antemortem interval. In vitro and in cultured cells, we show that tau catabolism is slowed by blockade of CatD proteolytic activity, including via competitive inhibition by Aβ42. Conclusions Our findings support a major role for CatD in the proteostasis of both Aβ and tau in vivo. To our knowledge, CatD-KO mice are the only model to develop detectable Aβ acumulation and profound tauopathy in the absence of overexpression of hAPP or human tau with disease-associated mutations. Given that tauopathy emerges from disruption of CatD, which can itself be potently inhibited by Aβ42, our findings suggest that impaired CatD activity may represent a key mechanism linking amyloid accumulation and tauopathy in AD.
Weakly-Supervised Transfer Learning With Application in Precision Medicine
Mao, Lingchao , Wang, Lujia , Hu, Leland , Eschbacher, Jenny, León, Gustavo De , Singleton, Kyle , Urcuyo, Javier , Sereduk, Chris , Tran, Nhan L. , Swanson, Kristin R. , Li, Jing , Singleton, Kyle W , Curtin, Lee A, Hawkins-Daarud, Andrea, Mao, Lingchao , Swanson, Kristin R , Tran, Nhan L , Leon, Gustavo De, Curtin, Lee , Hawkins‐Daarud, Andrea

IEEE Transactions on Automation Science and Engineering | October 23, 2023 | Volume: 21 | Issue: 4 | Pages: 6250-6264

10.1109/tase.2023.3323773 | PMID 40757183 Get It

Robot Motion Prediction by Channel State Information
Zandi, Rojin , Salehinejad, Hojjat , Behzad, Kian , Motamedi, Elaheh , Siami, Milad

2023 IEEE 33rd International Workshop on Machine Learning for Signal Processing (MLSP) | October 23, 2023 | Volume: No volume available | Issue: No issue available | Pages: 1-6

10.1109/mlsp55844.2023.10285960 Get It

Contrastive Representation of Channel State Information for Human Body Orientation Recognition in Interaction with Machines
Salehinejad, Hojjat , Hasanzadeh, Navid , Djogo, Radomir , Valaee, Shahrokh

2023 IEEE 33rd International Workshop on Machine Learning for Signal Processing (MLSP) | October 23, 2023 | Volume: No volume available | Issue: No issue available | Pages: 1-6

10.1109/mlsp55844.2023.10285895 Get It

A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2 -mutant AML
Huang, Ying , Lance, Jennie Rachel, Mao, Hsiaoyin, Dunbar, Andrew , McNulty, Samantha N. , Baer, Maria R. , Kovacsovics, Tibor , Blum, William , Schiller, Gary J. , Olin, Rebecca L. , Foran, James M. , Litzow, Mark R. , Patel, Prapti A. , Boyiadzis, Michael , Collins, Robert H. , Chervin, Jordan , Vergilio, Jo‐Anne, Heerema, Nyla A. , Rosenberg, Leonard, Chen, Timothy L. , Yocum, Ashley O. , Druggan, Franchesca , Marcus, Sonja, Stefanos, Mona , Borate, Uma , Burd, Amy , Byrd, John C. , Stein, Eytan M. , Huang, Ying , Cai, Sheng F , Litzow, Mark R. , Lin, Tara L , Druker, Brian J , Mims, Alice S , Byrd, John C , Druley, Todd E. , Li, Yan , Stock, Wendy , Lin, Tara L. , Foster, Matthew C , Shoben, Abigail B. , Levine, Ross L.

Blood Advances | October 23, 2023 | Volume: 8 | Issue: 2 | Pages: 429-440

10.1182/bloodadvances.2023010563 | PMID 37871309 Get It

Abstract Enasidenib (ENA) is an inhibitor of isocitrate dehydrogenase 2 (IDH2) approved for the treatment of patients with IDH2-mutant relapsed/refractory acute myeloid leukemia (AML). In this phase 2/1b Beat AML substudy, we applied a risk-adapted approach to assess the efficacy of ENA monotherapy for patients aged ≥60 years with newly diagnosed IDH2-mutant AML in whom genomic profiling demonstrated that mutant IDH2 was in the dominant leukemic clone. Patients for whom ENA monotherapy did not induce a complete remission (CR) or CR with incomplete blood count recovery (CRi) enrolled in a phase 1b cohort with the addition of azacitidine. The phase 2 portion assessing the overall response to ENA alone demonstrated efficacy, with a composite complete response (cCR) rate (CR/CRi) of 46% in 60 evaluable patients. Seventeen patients subsequently transitioned to phase 1b combination therapy, with a cCR rate of 41% and 1 dose-limiting toxicity. Correlative studies highlight mechanisms of clonal elimination with differentiation therapy as well as therapeutic resistance. This study demonstrates both efficacy of ENA monotherapy in the upfront setting and feasibility and applicability of a risk-adapted approach to the upfront treatment of IDH2-mutant AML. This trial is registered at www.clinicaltrials.gov as #NCT03013998.
Disentangling the Association Between Excess Thyroid Hormone and Cognition in Older Adults
Brito, Juan P. , Brito, Juan P , Papaleontiou, Maria

JAMA Internal Medicine | October 23, 2023 | Volume: 183 | Issue: 12 | Pages: 1332

10.1001/jamainternmed.2023.5618 | PMID 37870840 Get It